摘要
目的研究门冬胰岛素30(诺和锐30)与精蛋白生物合成人胰岛素30R(预混30R)治疗2型糖尿病(T2DM)的效果。方法选取某院T2DM患者92例(2017年1月~2019年1月),按照治疗方法分为A组、B组,各46例。A组采用诺和锐30治疗,B组采用预混30R治疗。比较两组治疗前、治疗3个月后血糖[空腹血糖(FBG)、餐后2 h血糖(2hPBG)、睡前血糖、糖化血红蛋白(HbA1c)]水平、不良反应及低血糖发生率。结果治疗3个月后A组FBG、2hPBG、睡前血糖、HbA1c水平均低于B组(P<0.05);A组不良反应总发生率为8.70%,B组不良反应总发生率为17.39%,组间比较差异无统计学意义(P>0.05);A组低血糖发生率4.35%低于B组17.39%(P<0.05)。结论与精蛋白生物合成人胰岛素30R对比,门冬胰岛素30治疗T2DM能显著降低血糖水平及低血糖发生率,二者安全性高。
Objective To study the effect of insulin aspart 30(Nuohe Rui 30)and protamine biosynthesis human insulin 30R(premixed 30R)in the treatment of type 2 diabetes(T2DM).Methods A total of 92 patients with T2DM in our hospital(January 2017 to January 2019)were enrolled.According to the treatment,they were divided into group A and group B,with 46 cases in each group.Group A was treated with Novo and 30,and group B was treated with premixed 30R.Blood glucose levels[fasting blood glucose(FBG),postprandial 2 h blood glucose(2hPBG),bedtime blood glucose,glycosylated hemoglobin(HbA1c)]levels,adverse reactions,and hypoglycemia were compared between the two groups before and after treatment.Results After 3 months of treatment,the levels of FBG,2hPBG,bedtime blood glucose and HbA1c in group A were lower than those in group B(P<0.05).The total incidence of adverse reactions in group A was 8.70%,and the total incidence of adverse reactions in group B was 17.39%.There was no significant difference between the two groups(P>0.05).The incidence of hypoglycemia in group A was 4.35%lower than that in group B(17.39%)(P<0.05).Conclusion Compared with protamine biosynthesis of human insulin 30R,insulin aspart 30 treatment of T2DM can significantly reduce blood glucose levels and hypoglycemia,and the safety of the two is high.
作者
胡新军
魏光谦
HU Xin-jun;WEI Guang-qian(Department of Pharmacy,Huangkang Aikang Hospital,Huangshi 435000,China)
出处
《中国处方药》
2020年第3期72-73,共2页
Journal of China Prescription Drug
